Skip to content

Investors / Press Releases


The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.


Filter Releases
 
Press Releases
Date Title and Summary View
Aug 11, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the pricing of an underwritten public offering of 21,100,000 American Depositary Shares ("ADSs") at a price to the public of $2.85 per ADS. The net proceeds to the company from this offering are expected to be approximatel...
Aug 10, 2016
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it has commenced an underwritten public offering of its American Depositary pursuant to a shelf registration.  All of the shares in the proposed offering are to be sold by Amarin.  The offering is subject to market co...
Aug 4, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/04/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and six months ended June 30, 2016, and provided an update on compan...
Aug 4, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/04/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the U.S. Food and Drug Administration (FDA) agreed to an amendment of the company's special protocol assessment (SPA) agreement for the REDUCE-IT cardiovascular outcomes study reaffirming concurrence on critical components...
Jul 28, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 07/28/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company'...
Jul 6, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 07/06/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a gen...
Jun 30, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/30/16 -- Amarin Corporation plc (NASDAQ: AMRN) announced that starting today Michael W. Kalb has joined its senior management team as senior vice president and chief financial officer. A seasoned financial executive, Mr. Kalb brings over 20 years of international financial operations and acc...
Jun 11, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/11/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced additional data on Vascepa (icosapent ethyl) presented at the annual meeting of the American Diabetes Association (ADA) supporting its efficacy in reducing concentrations of potentially atherogenic lipoproteins (lipoproteins th...
Jun 6, 2016
BEDMINSTER, NJ AND DUBLIN, IRELAND -- (Marketwired) -- 06/06/16 --  Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) will be presented at the upcoming American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans (June 10-14) and published as an abstract in the Diabe...
Jun 1, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/01/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a...
May 31, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/31/16 -- Amarin Corporation plc (NASDAQ: AMRN) announced today that the U.S. Food and Drug Administration (FDA) has determined that Vascepa® (icosapent ethyl) capsules are eligible for five-year, new chemical entity (NCE), marketing exclusivity pursuant to the Hatch-Waxman Amend...
May 20, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/20/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced the presentation of a poster at the annual meeting of the National Lipid Association (NLA) further characterizing the efficacy and safety of Vascepa® (icosapent ethyl) in women with very high triglyceride levels. ...
May 11, 2016
BEDMINSTER, NJ AND DUBLIN, IRELAND -- (Marketwired) -- 05/11/16 -- Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) and eicosapentaenoic acid (EPA) will be presented at the upcoming National Lipid Association 2016 Scientific Sessions in New Orleans (May 19-22). Data ...
May 5, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 05/05/16 --  Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2016, and provided an update on company ope...
Apr 28, 2016
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 04/28/16 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the c...
= add release to Briefcase